
Novo Nordisk A/S (NYSE:NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site in North Carolina, part of a global restructuring effort under new CEO Mike Doustdar.
The drugmaker has cutting even in frontline production roles as it looks to streamline costs and reposition itself in the heated weight-loss drug market.